Recruiting

Evaluating Atherosclerotic Disease Progression in Patients With Diabetes Mellitus

ClinicalTrials.gov IDNCT07237685

PhaseNot Applicable

Enrollment1000

SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Age18 Years and older

SexALL

I'm interested View official listing

Conditions studied

Type 2 Diabetes, Coronary Artery Disease (CAD), Atherosclerosis Cardiovascular Disease

About this study

People with type 2 diabetes have a much higher risk of heart disease. One common problem is when the blood vessels that supply the heart become narrowed or blocked by fatty deposits, called plaque. This makes it harder for blood to reach the heart and can lead to serious problems such as chest pain, heart attacks, or even death. This study will follow people with type 2 diabetes who have already had a special heart scan called a coronary CT angiography. This scan takes detailed pictures of the heart's blood vessels. The goal is to understand how heart disease changes over time in people with type 2 diabetes, by looking at repeat scans and other health information. By learning more about how plaque builds up or gets worse, researchers hope to find better ways to identify which patients are most at risk for future heart problems.

Primary outcomes

progression of total coronary plaque volume (mm3) (Between baseline (retrospective) and follow up CCTA (interval 2-5 years).)

Eligibility information

Inclusion Criteria: * Age over 18 years * Previous completion of CCTA scan for CAD assessment * Diagnosed with Type 2 Diabetes and currently receiving glucose lowering treatment * Sufficient image quality of the CCTA scan (at least 2/3 vessels of sufficient quality for assessment). Exclusion Criteria: * Inability to provide written informed consent * Presence of an unstable condition * Ingeligibility for CCTA acquisition due to severe renal dysfunction (eGFR ≤ 30 mL/min/1.73m²) or known hypersensitivity or contraindication to CT contrast agents * Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator * inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study * Baseline (routine care) CCTA performed \< 2 years or \> 5 years before inclusion

Study locations

Amsterdam University Medical Centers, Amsterdam, Netherlands
Cardiology Centers of the Netherlands, Amsterdam, Netherlands

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-27.